India's NSE to launch Platts‑based crude futures in tie-up with S&P Global Energy

India’s NSE to launch Platts‑based crude futures in tie-up with S&P Global Energy

India’s National Stock Exchange will launch exchange-traded derivatives based on Platts oil price benchmarks through a collaboration with S&P Global Energy, the bourse said on Monday. The move comes as India’s market regulator pushes to deepen commodity derivatives markets and attract greater institutional participation, including in metals and energy contracts. The products will offer tools…

Read More
PDS secures ₹450-crore sourcing contract from leading US value retailer

PDS secures ₹450-crore sourcing contract from leading US value retailer

PDS Limited has secured a strategic sourcing mandate worth around ₹450 crore from a leading United States-based value retailer, marking a significant step in strengthening its presence in the US market. The global fashion infrastructure platform said it has entered into a sourcing as a service (SaaS) contract with the retailer to provide end-to-end sourcing…

Read More
Godrej Consumer expects double-digit standalone sales growth in Q4FY26, flags crude concerns

Godrej Consumer expects double-digit standalone sales growth in Q4FY26, flags crude concerns

Godrej Consumer Products Ltd said on Monday, April 6, demand conditions and consumer sentiment remained steady in the domestic FMCG sector through Q4FY26, with trade channels normalising following the GST transition and food inflation easing. It added that policy tailwinds, including personal income tax relief and GST rationalisation, position the industry well to offset the…

Read More
Aurobindo arm CuraTeQ reports positive Phase 3 results for allergy drug BP11

Aurobindo arm CuraTeQ reports positive Phase 3 results for allergy drug BP11

Aurobindo Pharma’s wholly owned subsidiary, CuraTeQ Biologics, has reported positive top-line results from the Phase 3 trial of its omalizumab biosimilar, BP11, indicating comparable efficacy and safety to the reference drug, Xolair. An omalizumab biosimilar is a biologic similar to the branded drug Xolair, developed after patent expiry. Omalizumab is a monoclonal antibody that targets…

Read More
Raymond Realty Q4 update: Pre-sales jump 139% in MMR; collections modest

NCR real estate enters upcycle on ₹5,000 crore sales, wellness trend, Tier-2 expansion

India’s real estate sector is entering a structurally stronger growth phase, led by sustained ₹5,000 crore-plus annual sales by top developers, a sharp pivot towards wellness-led housing, and an aggressive expansion into emerging Tier-2 markets. The latest trigger comes from Max Estates Limited, which reported ₹5,305 crore in pre-sales for FY26, its second consecutive year…

Read More
Indian companies' $7 billion NDF hoard shows firms seized rupee arbitrage window

Indian companies’ $7 billion NDF hoard shows firms seized rupee arbitrage window

Indian companies’ activity in the non-deliverable forwards (NDF) market surged to over $7 billion on March 30, around seven times the average, signaling a rush to capture arbitrage opportunities created by banks unwinding positions following regulatory curbs. The unwinding followed the Reserve Bank of India’s imposition of restrictions on lenders’ net onshore open FX positions,…

Read More
PC Jeweller Q4 update: Revenue rises 32%, debt pared as recovery continues

PC Jeweller Q4 update: Revenue rises 32%, debt pared as recovery continues

PC Jeweller Ltd reported a 32% year-on-year rise in standalone revenue for the March quarter, while continuing to pare debt as part of its ongoing turnaround efforts. For FY26, the company said revenue grew around 49% year-on-year, supported by steady performance across quarters. During the quarter, it reduced outstanding bank debt by approximately 23% under…

Read More
SEBI's move to allow companies to buy back shares may stabilise markets, boost liquidity: Industry experts

SEBI’s move to allow companies to buy back shares may stabilise markets, boost liquidity: Industry experts

SEBI’s move to revive open market buybacks could bring a structural buyer back into equities, helping absorb selling pressure and stabilise markets amid volatility. As Bhavesh Shah, Managing Director and Head of Investment Banking at Equirus Capital, pointed out, “earlier it used to be a panic selling… now there’s someone in the market out there…

Read More